Pak Kyoungjune, Kim So Jung, Shin Seunghyeon, Kim Keunyoung, Kim Bum Soo, Kim Seong Jang, Cha Wonjae, Jang Jeon Yeob, Lee Byung Joo, Jeon Yun Kyung, Kim Sang Soo, Kim Bo Hyun, Kim In Joo
Nuklearmedizin. 2017;56(5):177-183. doi: 10.3413/Nukmed-0898-17-05. Epub 2018 Jan 4.
We assessed patient discomfort and identified factors predictive of discomfort while receiving radioactive iodine (RAI) ablation.
Between August 2015 and April 2016, 52 patients with differentiated thyroid cancer were enrolled in this study. All patients received recombinant human thyroid stimulating hormone (rhTSH) aided RAI ablation using 3.7 GBq or 5.55 GBq of RAI. Discomfort during their stay for RAI ablation was evaluated using a symptom questionnaire. We analyzed the relationship between the patient's clinical data and the scores for the 15 items of the symptom questionnaire. We compared scores of questionnaires between male and female, under 45 years old and 45 and older, RAI activity of 3.7 GBq and 5.55 GBq. Also, scores of daily questionnaires were tested for differences.
Most patients did not have severe discomfort, but some patients had mild discomfort during their stay for RAI ablation, despite using rhTSH. Important determinants of discomfort were sex and age. Female patients reported more symptoms of fatigue, facial edema, cold intolerance, and nausea. Older patients (45 and older) complained of insomnia more often. However, the dose of RAI ablation (3.7 GBq vs 5.55 GBq) did not affect the scores of questionnaires.
Sex and age were important predictors of patient's discomfort during RAI ablation. Clinicians need to explain more about treatment and predicted discomforts to such patients before RAI ablation.
我们评估了接受放射性碘（RAI）消融治疗的患者的不适情况，并确定了预测不适的因素。
2015年8月至2016年4月期间，52例分化型甲状腺癌患者纳入本研究。所有患者均接受重组人促甲状腺激素（rhTSH）辅助的RAI消融治疗，使用3.7GBq或5.55GBq的RAI。使用症状问卷评估他们在接受RAI消融治疗期间的不适情况。我们分析了患者的临床数据与症状问卷15项得分之间的关系。我们比较了男性和女性、45岁以下和45岁及以上、RAI活度为3.7GBq和5.55GBq的问卷得分。此外，还对每日问卷得分进行了差异检验。
大多数患者没有严重不适，但一些患者在接受RAI消融治疗期间有轻度不适，尽管使用了rhTSH。不适的重要决定因素是性别和年龄。女性患者报告有更多疲劳、面部水肿、不耐寒和恶心的症状。老年患者（45岁及以上）更常抱怨失眠。然而，RAI消融剂量（3.7GBq与5.55GBq）并未影响问卷得分。
性别和年龄是RAI消融治疗期间患者不适的重要预测因素。临床医生在RAI消融治疗前需要向此类患者更多地解释治疗情况和预测的不适。
